Canada’s Free-Market Example for the SEC
Op-ed by Peter St. Onge, Senior Fellow at the MEI, and John Hartsel, Director of Research & Portfolio Manager at Donald Smith & Co., published on May 17 in The Wall Street Journal.
Viewpoint explaining how Health Canada’s reform of the pricing mechanism for new drugs could delay their introduction
The Canadian government is planning to change the way prices are set for new patented drugs and cut the maximum prices at which these drugs can be sold by up to 70%. But this reform could prove very costly for patients. If it goes forward and fails to take into account the adverse effects of reference pricing systems, which have been well documented by various international bodies, Canadians could see their access to new drugs slowed down or even compromised.
Viewpoint showing that to ensure the best possible access to care, health professionals should be able to use all their skills
Quebec’s Health Minister recently announced that she wanted specialized nurse practitioners (SNPs) to be able to make diagnoses, as is the case everywhere else in Canada. The Collège des médecins du Québec (CMQ) ended up making peace with the idea, while the Fédération des médecins omnipraticiens du Québec (FMOQ) is still not on board, claiming that this act must be reserved to physicians. Is this resistance justified?
Viewpoint examining the numerous reasons to question the effectiveness of a soda tax
Earlier this year, the Quebec government formed a committee whose stated goal was to propose a soda tax, for the purpose of reducing the prevalence of obesity. Yet there are numerous reasons to question the effectiveness of this measure. Indeed, when a tax modifies the price of a good, there is no guarantee that the replacement product will be better for one’s health than the taxed product.